Please assess the completion status of the following clinical trial:

Trial Title: Depressed Mood Improvement Through Nicotine Dosing 2

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 60 years;~2. Diagnosis of major depressive disorder, single or recurrent episode (DSM5);~3. On a stable therapeutic dose of an allowed selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI) for at least 8 weeks;~4. Severity: Montgomery-Asberg Depression Rating Scale (MADRS) score ≥ 15;~5. Cognition: Mini-Mental State Examination (MMSE) score ≥ 24;~6. Fluent in English~Exclusion Criteria:~1. Other Axis I psychiatric disorders, except for generalized anxiety disorder (GAD) symptoms occurring in a depressive episode;~2. Use of other medications for depression, e.g., bupropion or augmenting agents, although short-acting sedatives are allowed (see below);~3. Any use of tobacco or nicotine in the last year;~4. Living with a smoker or regular exposure to secondhand smoke;~5. History of alcohol use disorder or substance use disorder of moderate or greater severity (endorsing 4 or more of the 12 criteria) in the last 12 months;~6. Acute suicidality;~7. Acute grief (\<1 month);~8. Current or past psychosis;~9. Primary neurological disorder, including dementia, stroke, epilepsy, etc.;~10. MRI contraindication;~11. Electroconvulsive therapy or transcranial magnetic stimulation in last 2 months;~12. Current or planned psychotherapy;~13. Allergy or hypersensitivity to nicotine patches;~14. In the last 4 weeks, regular use of drugs with central cholinergic or anticholinergic properties or moderate / severe CYP2A6 inhibitors /inducers.

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transdermal Nicotine Patch (Type: EXPERIMENTAL): Participants will wear open label transdermal nicotine patch daily for 12-15 weeks. They will apply study patch each morning and remove at bedtime. Dosage will begin at 3.5mg patch / day, increasing to a possible maximum of 21mg patch / day.

Based on this trial design, predict the completion outcome and termination type (if applicable).